Volume 13, Issue 6 (November-December 2014)
Payesh 2014, 13(6): 705-712 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammad Ebrahim Khamseh, Manouchehr Nakhjavani, Farhad Hosseinpanah, Saeid Kalantari, Mojgan Sanjari, Manouchehr Mohammadbeigi. Metabolic control and prevalence of diabetes related complications in patients with type 2 diabetes: baseline results of the A1chieve study. Payesh 2014; 13 (6) :705-712
URL: http://payeshjournal.ir/article-1-270-en.html
URL: http://payeshjournal.ir/article-1-270-en.html
Mohammad Ebrahim Khamseh 
1, Manouchehr Nakhjavani2 , Farhad Hosseinpanah3 , Saeid Kalantari3 , Mojgan Sanjari4 , Manouchehr Mohammadbeigi5
1, Manouchehr Nakhjavani2 , Farhad Hosseinpanah3 , Saeid Kalantari3 , Mojgan Sanjari4 , Manouchehr Mohammadbeigi5
1- Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
2- Vali-asr hospital, Tehran University of Medical sciences, Tehran, Iran
3- Obesity Research Center, Research Institute for Endocrine Science, Shahid Beheshti University of Medical Science, Tehran, Iran
4- Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran
5- Iranian Diabetes Societies, Tehran, Iran
2- Vali-asr hospital, Tehran University of Medical sciences, Tehran, Iran
3- Obesity Research Center, Research Institute for Endocrine Science, Shahid Beheshti University of Medical Science, Tehran, Iran
4- Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran
5- Iranian Diabetes Societies, Tehran, Iran
Abstract: (4426 Views)
Objective: The aim of this study was to assess the safety and efficacy of treatment with insulin analog Novomix30 in Iranian patients with type 2 diabetes using the results of the A1chieve study.
Methods: The A1chieve study was a 24 week, open-label, multicenter, observational study of people with type 2 diabetes. The study was conducted in 28 countries across four continents on 66,726 people with type 2 diabetes, both insulin users and non-insulin users, to assess the safety and efficacy of Novomix30. This article reports the results of 919 Iranian patients with type 2 diabetes treated with insulin Novomix30.
Results: After 24 weeks treatment with Novomix30, HbA1c reduced significantly (P<0.001). Despite a significant reduction in fasting blood sugar and postprandial sugars, the incidence of severe and nocturnal hypoglycemia was significantly decreased in prior insulin users. The mean arterial blood pressure decreased significantly and the quality of life improved in all patients.
Conclusion: Insulin Novomix30 was well tolerated despite good glycemic control and the incidence of hypoglycemia was not increased in Iranian patients with type 2 diabetes.
Methods: The A1chieve study was a 24 week, open-label, multicenter, observational study of people with type 2 diabetes. The study was conducted in 28 countries across four continents on 66,726 people with type 2 diabetes, both insulin users and non-insulin users, to assess the safety and efficacy of Novomix30. This article reports the results of 919 Iranian patients with type 2 diabetes treated with insulin Novomix30.
Results: After 24 weeks treatment with Novomix30, HbA1c reduced significantly (P<0.001). Despite a significant reduction in fasting blood sugar and postprandial sugars, the incidence of severe and nocturnal hypoglycemia was significantly decreased in prior insulin users. The mean arterial blood pressure decreased significantly and the quality of life improved in all patients.
Conclusion: Insulin Novomix30 was well tolerated despite good glycemic control and the incidence of hypoglycemia was not increased in Iranian patients with type 2 diabetes.
type of study: Descriptive |
Accepted: 2014/01/12 | ePublished ahead of print: 2014/10/29 | Published: 2014/10/29
Accepted: 2014/01/12 | ePublished ahead of print: 2014/10/29 | Published: 2014/10/29
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |